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Abstract
Background: Miltefosine (MF) is the first oral compound used in the chemotherapy against leishmaniasis. Since the
mechanism of action of this drug and the targets of MF in Leishmania are unclear, we generated in a step-by-step manner
Leishmania major promastigote mutants highly resistant to MF. Two of the mutants were submitted to a short-read whole
genome sequencing for identifying potential genes associated with MF resistance.
Methods/Principal Findings: Analysis of the genome assemblies revealed several independent point mutations in a P-type
ATPase involved in phospholipid translocation. Mutations in two other proteins—pyridoxal kinase and a-adaptin like
protein—were also observed in independent mutants. The role of these proteins in the MF resistance was evaluated by
gene transfection and gene disruption and both the P-type ATPase and pyridoxal kinase were implicated in MF
susceptibility. The study also highlighted that resistance can be highly heterogeneous at the population level with
individual clones derived from this population differing both in terms of genotypes but also susceptibility phenotypes.
Conclusions/Significance: Whole genome sequencing was used to pinpoint known and new resistance markers associated
with MF resistance in the protozoan parasite Leishmania. The study also demonstrated the polyclonal nature of a resistant
population with individual cells with varying susceptibilities and genotypes.
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Introduction
Leishmania is a protozoan parasite responsible for a spectrum of
diseases collectively known as leishmaniasis in tropical and
subtropical areas of the world [1]. There is no effective vaccine
for the prevention of this parasitic disease and its control relies on
chemotherapy. The arsenal of available drugs is limited with most
compounds being compromised by toxicity, cost, or resistance [2].
The alkyl-lysophospholipid analogue miltefosine (MF), a drug
initially developed as an antitumoral compound, was the first
effective oral drug against Leishmania. It has been successfully used
in the last decade for the treatment of visceral leishmaniasis [3–5].
The exact mode of action of MF is not well understood, but it was
shown to induce changes in the biosynthesis of phospholipids and
the metabolism of alkyl-lipids in Leishmania [6], in addition to
induce an apoptotic cell death [7,8]. The uptake of MF and other
alkyl-glycerophospholipids in Leishmania requires a P-type ATPase,
named miltefosine transporter (MT), which is responsible for the
translocation of phospholipids from the exoplasmic to the
cytoplasmic leaflet of the plasma membrane of the parasite [9].
Based on findings in yeast [10,11], the uptake of MF in L. donovani
was further shown to require a protein named LdRos3, the b-
subunit of the MT [12]. Differences in susceptibility to alkyl-
lysophospholipids between Leishmania species [13,14] has recently
been associated with the low expression of this MF translocation
machinery in species displaying a lack of intrinsic MF susceptibility
[15].
Resistance to MF in Leishmania [12] and other organisms [16,17]
involved a decreased accumulation of the drug due to reduced
uptake or increased efflux. In L. donovani, a drastic reduction (40-
fold decrease) in the ability to internalize the drug was shown to be
accompanied by a decreased content of unsaturated phospholipids
in the plasma membrane of resistant parasites [18,19]. The
acquisition of inactivating mutations or the deletion of the MT
gene in L. donovani [9,20] was shown to drastically increase MF
resistance both in vitro and in vivo. In addition, the overexpression of
ABCG4 and ABCG6, two ABC proteins localized to the flagellar
pocket and plasma membrane of the parasite, was associated with
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1512an increased resistance to several alkyl-lysophospholipid analogues
in Leishmania [21–23]. Parasites overexpressing ABCG4 or ABCG6
had a reduced accumulation of fluorescent phospholipids and
[
14C]-MF, which suggested an enhanced outward translocation of
the drug across the plasma membrane. A L. tropica mutant resistant
to daunomycin harboring an amplification of the ABC protein
ABCB4 (MDR1) was also shown to display cross-resistance to MF
[24], although the absence of similar amplicons in MF-resistant L.
donovani suggested that the amplification of ABCB4 (MDR1) is not
a frequent mechanism of resistance to MF [25]. Finally, functional
cloning experiments identified a hypothetical gene in L. infantum
whose increased expression conferred resistance to MF and
antimony [26].
The central role of MF in the control of leishmaniasis warranted
further studies on its mode of action and the mechanisms involved
in resistance. Indeed, the ease with which MF-resistant parasites
are selected in vitro suggests that clinical failures resulting from MF-
resistant isolates are likely. In this study, we sought to determine
the mutational events involved in MF resistance on a whole
genomic scale by sequencing the entire genome of two L. major
mutants independently selected for high level MF resistance in vitro.
Methods
Cell lines, culture conditions and transfections
L. major Friedlin and L. infantum (MHOM/MA/67/ITMAP-
263) wild-type promastigotes were grown at 25uC in SDM-79
medium supplemented with 10% heat inactivated fetal bovine
serum and 10 mg/ml hemin. The L. major Friedlin MF80.1,
MF80.2, MF80.3 and MF80.5 mutants were selected from a
cloned parental population using a stepwise selection until they
were resistant to 80–100 mM MF. MF was purchased from
Cayman Chemical (Ann Harbor, USA). To obtain clones derivied
from the mutants 5.3, 10.3, 15.3 40.3 and 80.3, parasites were
spread on SDM-agar (1% Noble Agar, Nunc) plates in absence of
MF.
Partial revertants were obtained by culturing the resistant lines
in the absence of MF for 30 passages. The L. infantum MF200.3
and MF200.5 mutants selected for MF resistance had been
generated previously [27]. Growth curves were obtained by
measuring absorbance at 600 nm as previously described [28].
Gene transfection was performed by electroporation as reported
previously [29]. Statistical significance was determined by
Student’s t-test. Significance was considered as P,0.05.
DNA manipulations
Total DNA was isolated using DNAzol reagent (Invitrogen) as
recommended by the manufacturer. For quantitative Southern
blots, the genomic DNA was digested with appropriate restriction
enzymes and migrated in 0.8% agarose gels. Southern blots,
hybridizations and washes were performed following standard
protocols [30]. Probes were obtained by amplifying the upstream
or downstream regions of the gene studied. The pSP72aHYGa-
MT construct was generated by the amplification of the MF
transporter gene from L. major Friedlin (LmjF13.1350) with
primers containing the restriction enzymes XbaI and HindIII
(Table S1) and cloned in the respective plasmid. All the constructs
were checked by sequencing with internal primers (Table S1).
Similarly, the genes pyridoxal kinase (LmjF30.1250) and a-adaptin
like protein (LmjF07.0050) were cloned in pSP72aNEOa or
pSP72aHYGa[31] at XbaI and HindIII sites.
The pyridoxal kinase gene (LmjF30.1250) inactivation cassette
was generated by overlap extension PCR [32,33] using the primer
A-PK-KO and primer B-PK-NEO-KO to amplify a region of
550-bp upstream of the gene; primer E-PK-NEO-KO and primer
F-PK-KO to amplify a DNA fragment of 600-bp downstream of
the gene; and primers C-PK-NEO-KO and primer D-PK-NEO-
KO, to amplify the NEO gene. The fragment generated was
cloned in the pGEM-T-easy vector leading to the pGEM-T-KO-
NEO-PK. The LmjF30.1250 inactivation cassette was isolated
from pGEM-KO-NEO-PK by an EcoRI digestion and transfected
in L. major Friedlin. A second inactivation cassette containing a
HYG marker was generated using the A and F primers described
above along with primers B-PK-HYG-KO, D-PK-HYG-KO and
E-PK-HYG-KO (Table S1). The fragment generated was cloned
in the pGEM-T-easy vector leading to the second construct
pGEM-T-KO-HYG-PK to inactivate the PK gene. The integra-
tion of the inactivation cassette at the LmjF30.1250 locus was
confirmed by PCR and Southern blots. A rescue vector containing
the wild-type gene was generated by PCR amplification using the
primers PKF and PKR, cloned in pGEM-T easy vector,
sequenced and then subcloned in pSP72aZEOa generating the
plasmid pSP72aZEOa-PK. All the primers used are listed in
Table S1.
Genome resequencing and analysis
Genomic DNAs were prepared from mid-log phase cultures of
L. major Friedlin mutants MF80.3 and MF80.5 and L. major
Friedlin wild-type parasites and sequenced using Illumina Genome
AnalyzerIIx short 76-nucleotide single-end reads. We had a
genome coverage over 50-fold for the two independent mutants
and the wild-type parasite. This strategy allowed us to identify
point mutations and small indels (#3 bp) when comparing with
the known genome sequence of L. major Friedlin [34].
Data analysis
Sequence reads from each clone were aligned to the L. major
Friedlin reference sequence available (TriTrypDB version 3.3)
[35] using the software bwa (bwa aln, version 0.5.9) with default
parameters [36]. The maximum number of mismatches was 4, the
seed length was 32 and 2 mismatches were allowed within the
seed. The detection of single nucleotide polymorphisms (SNPs)
was performed using samtools (version 0.1.18), bcftools (distributed
Author Summary
Leishmania spp. are parasitic protozoa responsible for a
spectrum of diseases known as leishmaniasis. There are
few drugs available for the treatment of these diseases,
and miltefosine is the first oral drug used in treatment of
visceral leishmaniasis, a form of the disease that can be
lethal if not treated. In this study, we seek to understand
the mechanism of action and identify targets of the drug
by generating promastigote mutants highly resistant to
miltefosine. Two independent mutants were submitted to
short read whole genome sequencing. Genome analysis of
these mutants has permitted us to identify point
mutations in three genes (P-type ATPase, pyridoxal kinase
and a-adaptin like protein) that were also present in other
independent miltefosine resistant mutants. Some of the
new genes identified here could be useful as potential
markers for miltefosine resistance in Leishmania. Moreover,
our approach has permitted us to highlight that resistance
can be highly heterogeneous at the population level with
individual clones derived from this population differing
both in terms of genotypes but also susceptibility
phenotypes. This may have practical applications while
studying resistance.
Genome Sequencing of Resistant Leishmania
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a minimum of three reads to call a potential variation prior to
further analysis. The sequence data for L. major Friedlin wild-type,
MF80.3 and MF80.5 are available at the EMBL European
Nucleotide Archive (http://www.ebi.ac.uk/ena) (accession num-
ber ERP000917; samples ERS056015, ERS056016 and
ERS056017 corresponding to L. major Friedlin wild-type;
MF80.3 and MF80.5 respectively). Several python (version 2.4.3)
scripts and bash (version 3.2) scripts were created to further
analyse the data. The quality assessment software samstat (v1.08)
was used to generate quality reports [38].
All the putative point mutations detected by whole genome
sequencing were verified by PCR amplification and conventional
DNA sequencing. The primers were designed using Primer3
program [39].
Results
Characterization of L. major Friedlin MF-resistant mutants
Four independent L. major Friedlin MF-resistant mutants
(MF80.1, 80.2, 80.3 and 80.5) were generated by a stepwise
fashion until they reached a MF EC50 of at least 80 mM (Fig. 1).
The MF80.3 and MF80.5 lines displayed the highest levels of
resistance, with at least 15 fold increase in resistance compared to
the wild-type (WT) parent. The phenotype of MF resistance
appeared relatively stable, as culturing the parasites in absence of
MF for 30 passages led to only a small albeit significant decrease in
resistance in both MF80.3 and MF80.5 (Fig. 1, lanes 6, 7) but also
in MF80.1 and MF80.2 (data not shown). Because of the small
decrease of resistance, we tested whether MF resistance in our
mutants was accompanied by gene amplification, a frequent
mechanism of drug resistance in Leishmania [40,41]. However,
neither alkaline lysis nor clamped homogeneous electrical field
electrophoresis revealed the presence of circular or linear
amplicons in any of MF resistant mutants (results not shown).
Whole-genome sequencing of L. major Friedlin MF-
resistant mutants
The genomes of one clone derived from the wild-type L. major,
MF80.3 and MF80.5 mutants were resequenced using the single-
end reads Illumina platform. We obtained a total of 30,083,681,
28,369,175 and 28,259,044 reads leading to an average genome
coverage of 52-fold for the wild-type L. major Friedlin strain and
MF80.3 and MF80.5 respectively. In all cases, close to 80% of the
reads were aligned to the L. major Friedlin genome. The unmapped
reads (25.1%, 20.2% and 18.5% respectively for L. major wild-type,
MF80.3 and MF80.5) had low mean base quality according to
samstat (version 0.08) [38] with slightly less than half mapping to
mitochondrial DNA. Read depth coverage can be used to predict
copy number variations being either amplifications or deletions.
We investigated copy number of chromosomal regions by read
depth coverage for each chromosome of the resistant mutants
which were compared to the wild-type sensitive L. major Friedlin.
This analysis did not reveal changes in read depth between
sensitive and resistant isolates that would constitute signatures of
copy variation, hence confirming the absence of gene amplifica-
tion in these mutants but also indicating no obvious gene/locus
deletion or changes in ploidy (data not show). While no change in
copy number was related to resistance, we found that some
chromosomes were polyploid in both L. major Friedlin wild-type
cells and in the two MF-resistant clones. Chromosome 1, 5, 11, 20
and 23 were in three copies while chromosome 31 was at least in
six copies in the wild-type cells but also in the mutants (Fig. S1A–
C).
While no changes in copy number were observed, the
resequencing of the L. major Friedlin wild-type strain and of the
mutants differed from the published sequence [34]. Indeed, 20
homozygous (Table S2) and 42 heterozygous SNPs (Table S3)
were observed. The polymorphic sites identified here in the coding
sequences were highlighted by resequencing the wild-type Friedlin
strain, the two MF-resistant strains and also other L. major Friedlin
Figure 1. Miltefosine susceptibilities of Leishmania major mutants and wild-type parasites. The EC50 values were determined by culturing
promastigote parasites in the presence of increasing concentrations of MF. The average of three independent experiments is shown. EC50 values for
MF in L. major wild-type parasites (1); MF80.1 (2); MF80.2 (3);MF80.3 (4); MF80.5 (5) MF-resistant mutants. The MF80.3 and MF80.5 mutants were
grown in the absence of MF for 30 passages (6 and 7 respectively). * p,0.05; ** p,0.01.
doi:10.1371/journal.pntd.0001512.g001
Genome Sequencing of Resistant Leishmania
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majority of polymorphisms (68%) changed the amino acids of the
encoded proteins (Table S2 and S3). Thus, the majority of putative
mutations found by this next-generation sequencing approach
corresponded to natural polymorphisms present in the parental
clones and that were not selected for during the drug pressure.
However, whole genome sequencing of the two miltefosine
resistant mutant clones also revealed genuine mutations (Table 1).
Indeed, a three nucleotide deletion was seen in in the MT gene of
MF80.3 (LmjF13.1530) and a transition mutation leading to a
mutated G852D protein version was observed in mutant MF80.5
(Table 1). These mutations highlighted by next generation
sequencing were confirmed by PCR amplification and standard
DNA sequencing and the same validation approach was used for
all other mutations that will be discussed afterwards. Interestingly,
another mutation was in a common gene for both mutants. It
corresponded to the LmjF30.1250 gene that code for a putative
pyridoxal kinase (PK). The MF80.3 mutant acquired a mutation
in both alleles that led to a T216M amino acid substitution while
one wild-type allele and one allelic version leading to a G269D
protein were observed in the MF80.5 line (Table 1). Other
mutations were specific to either MF80.3 or MF80.5. Three
heterozygous mutations in LmjF15.0800 and LmjF.27.1250, both
coding for hypothetical proteins, and in LmjF36.5880 coding for a
small GTPase were found in MF80.3 (Table 1). The sequences of
the MF80.5 clone allowed the detection of a homozygous
mutation in LmjF07.0050 coding for an a-adaptin like protein
and an heterozygous mutation in the hypothetical protein coding
gene LmjF21.0835 (Table 1).
Since few genuine point mutations were highlighted by whole
genome sequencing, we next amplified and sequenced these
specific mutated genes in additional L. major and L. infantum MF
resistant mutants that were available. This targeted approach
revealed that only the MT and PK genes were mutated in the four
independent L. major resistant mutants (Table 2), and that MT was
also mutated in the two L. infantum mutants investigated (Table 2).
The mutations were at different sites in the L. infantum or L. major
mutants (Table 2), but these mutations occurred at conserved sites
within the MT protein (Fig. S2). The targeted sequencing of the
PK gene in the other L. major mutants revealed that they were also
heterozygous for mutations leading to G269D or T216M amino
acid substitutions, respectively (Table 2). However, the PK gene
was not mutated in the two L. infantum MF resistant mutants
analysed (Table 2). The LmjF07.0050 a-adaptin gene was the only
other mutation that was not strain-specific since the gene was also
mutated in the two independent L. infantum MF resistant mutants
(Table 2 and Fig. S3). The four remaining mutations highlighted
by next-generation sequencing were unique to either MF80.3 or
MF80.5 (Table 2). Surprisingly, we did not observe point
mutations in the Ros3 b-subunit of MT, a known MF-resistance
gene [12], in any of the miltefosine resistant mutants analyzed
(Table 2).
We were intrigued by the diversity of mutations in the MT gene
between the different mutants (Table 2) suggesting that mutations
in MT could be polyclonal. We investigated the MT status in
clones (and population) isolated at intermediate passages leading to
the generation of MF80.3. Most interestingly, no mutations in MT
were found in any of the resistant populations leading to MF80.3
(Fig. 2), suggesting indeed that resistance can be polyclonal, and
since no clones are dominant, mutations can be missed when
sequencing the population. In none of the 10 clones investigated
derived from MF5.3, MF10.3, or MF15.3 could we detect any
mutations in MT. However in the 10 clones derived from MF40.3
where the MT gene was sequenced, all clones had a mutated MT
and 5 different genotypes were observed. Three clones had a three
nucleotide deletion leading to the deletion of M547, two had a
deletion of M546, one clone had a D567V mutation and 4 clones
had a L235R mutation (3 homozygous and one heterozygous)
(Fig. 2). The three clones derived from MF80.3 had the deletion of
M547 (Fig. 2). The situation was different in the lineage leading to
MF80.5. Indeed, the homozygous G852D mutation found in the
MT of the sequenced clone (Table 1) was also detected in the
MF80.5 population but also in the MF60.5 population and the
mutation was heterozygous at the earlier passages of MF20.5 and
MF40.5 (Table 3). Similarly to the lineage leading to MF80.3,
mutations in the MT gene were observed only at the highest drug
Table 1. Gene mutations identified in L. major miltefosine-resistant mutants.
A. MF80.3
Chromosome Type Start End
Reference base
in GeneDB
Base in
MF80.3
L. major
gene ID
Position in
the gene
Amino acid
change
13 Deletion 567388 567391 TGA -TGA LmjF13.1530 1640–1642 M547del
15 SNP 368510 C C or T LmjF15.0800 1531 H511Y
27 SNP 526263 C C or G LmjF27.1250 407 T136R
30 SNP 427336 C T LmjF30.1250 647 T216M
36 SNP 2256582 C C or G LmjF36.5880 537 F179L
B. MF80.5
Chromosome Type Start End
Reference base
in GeneDB
Base in
MF80.5
L. major
gene ID
Position in
the gene
Amino acid
change
7 SNP 19641 G C LmjF07.0050 2284 D762H
13 SNP 566476 C T LmjF13.1530 2555 G852D
21 SNP 305528 C C or G LmjF21.0835 868 L290V
30 SNP 427495 G G or A LmjF30.1250 806 G269D
Summary of all mutations (single nucleotide mutations (SNPs) and indels) identified in clones derived from L. major MF80.3 (A) and MF80.5 (B) miltefosine resistant
mutants using the software BWA and Samtools.
doi:10.1371/journal.pntd.0001512.t001
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LmjF30.1250 appeared during the first selection of MF selection in
both MF80.3 and MF80.5 mutants (Fig. 2 and Table 3). While the
mutation remained heterozygous in the MF80.5 lineage (Table 3),
the number of mutated alleles in the PK gene in the MF80.3
lineage, with the exception of MF40.3 (see below), correlated with
resistance levels (Fig. 2).
Functional analysis of genes involved in MF resistance
T h er o l ei nr e s i s t a n c eo ft h eMT mutations highlighted in one
clone of MF80.3 and MF80.5 was further studied by gene
transfection experiments. Episomal transfection of the wild-type copy
of MT sensitized wild-type cells to MF by 3-fold whereas transfections
of the G852D or M547- versions cloned in the same vector did not
change the phenotype (Fig. 3A, bars 2–4). Transfection of the wild-
type gene copy of MT in MF80.3 and MF80.5 sensitized the mutants
to MF although not to wild-type levels (Fig. 3B and C, bar 2).
Significantly, transfection of the mutated versions of MT neither
sensitized the mutant cells nor the wild-type cells, showing that these
mutations alter the function of MT (Fig. 3, bars 3, 4).
The role of the PK and a-adaptin-like proteins that were mutated
in more than one mutant (Table 1), in MF resistance was also
assessed by gene transfection experiments. In contrast to the MT
gene, however, the overexpression of WT versions of the PK or a-
adaptin-like genes failed to alter the MF resistance levels of L. major
WT (Fig. 3A, bars 5 and 6), MF80.3 (Fig. 3B, bars 5 and 6) and
MF80.5 mutants (Fig. 3C, bars 5 and 6). Transfection of mutated
versions of the PK and a-adaptin-like genes also failed to alter the
MF susceptibility status of the wild-type L. major Friedlin strain (data
not shown). The PK mutations were acquired during the first step of
selection in both lines, prior to the selection of mutations in the MT
(Fig. 2 and Table 3). To further investigate the role of PK in MF
resistance, we investigated clones at differentlevel of selection giving
rise to MF80.3. The genotype of PK varied with clones being either
heterozygous (WT/T216M) or T216M homozygous mutants
(Fig. 2). The level of resistance to MF and the number of mutated
PK alleles was not straightforward but a wild-type PK allele has
never been found in MF resistant cells (Fig. 2, and Table 3). Only
heterozygous mutations were found in clones derived from MF5.3
but in MF10.3 we found a mixture of clones with either
homozygous or heterozygous mutations in PK, while all clones
derived from MF15.3 had homozygous T216M mutation in PK
(Fig. 2). In the MF40.3 clone, we observed cells that were
surprisingly heterozygous for PK but these cells have a mutation
in MT, a mutation not present in the MF15.3 derived clones (Fig. 2)
and possibly the establishment of mutations in MT is facilitated in
cells still having some wild-type PK activity. When the MF40.3
population was selected for higher resistance to yield MF80.3, all
clones exhibited the same PK homozygous mutation (Fig. 2).
We also investigated the susceptibility levels of selected clones
for the earlier passages. While, as expected, the population of
MF5.3, MF10.3 and MF15.3 became more and more resistant to
MF (Fig. 4) we found variations in the EC50 between the individual
clones derived from the population. Indeed, some clones were as
resistant as the population and others had susceptibilities close to
wild-type levels (Fig. 4). For example, clones 4 and 10 derived from
MF5.3 had the same genotype (for MT and PK) but clone 4 had
an EC50 close to wild-type while clone 10 was resistant to MF
(Fig. 4). Similarly, the cloning of MF10.3 led to parasite with either
homozygous (clone 3) or heterozygous (clone 7) mutations in PK
and clone 3 was found to be more resistant (Fig. 4). However,
clones 1 and 2 derived from MF15.3 had the same genotype (for
MT and PK) but their resistance to MF varied (Fig. 4).
While no susceptibility phenotype was observed in transfecting
PK in MF80.3 (Fig. 3B), the MF15.3 mutant is homozygous for
the T216M PK substitution and still has a wild-type version of MT
(Fig. 2). The transfection of the wild-type PK-containing plasmid
in MF15.3 resulted in the reversion of MF resistance (Fig. 5). In
contrast, the transfection of theT216M version had no effect on
MF susceptibility (Fig. 5). We next investigated whether deletion of
PK was possible and tested how this could modulate MF
susceptibility. Two replacement cassettes containing the neomycin
phosphotransferase (NEO) or hygromycin phosphotransferase
(HYG) genes were generated for replacing PK (Fig. 6). Since
Leishmania is diploid, the sequential integration of the NEO or HYG
inactivation cassette should lead to a 1.5 and 1.8 kb DNA
fragment, respectively, in addition to the remaining WT PK
fragment of 1.2 kb when the DNA of transformants is digested
with PstI and hybridized to a 39UTR PK probe corresponding to a
600 bp fragment upstream the PK gene stop codon (Fig. 6A). The
generation of NEO single disruptant led to the expected genotype
(Fig. 6B, lane 2). Introduction of the HYG construct into a PK/
NEO parasite indicated that while both NEO and HYG alleles
integrated properly, there was always a remaining wild-type allele
(Fig. 6B, lane 3), a phenomenon often observed when attempting
to inactivate essential genes [42–45]. Parasites with a single allele
of PK inactivated with NEO were more sensitive to MF than the
control-transfected parasites (Fig. 6C) and this phenotype could be
partially rescued by the addition of an episomal construct
encoding a functional copy of PK (Fig. 6C).
Table 2. Mutations potentially involved in miltefosine resistance in Leishmania.
Genes / mutants MF80.1 MF80.2 MF80.3 MF80.5 Li MF200.3 Li MF200.5
Miltefosine transporter (LmjF13.1530) P782T W895* M547del G852D W617* G565R
Ros3 (LmjF32.0510) N oN o N oN o N oN o
Pyridoxal kinase (LmjF30.1250) G269G G269D T216T T216M T216M G269G G269D No No
a-Adaptin like protein (LmjF07.0050) No No No D762H C54F F58L
Hypothetical protein (LmjF15.0800) ND ND H511H H511Y No ND ND
Hypothetical protein (LmjF21.0835) No No No L290L L290V No orthologue
in L. infantum
No orthologue
in L. infantum
Hypothetical protein (LmjF27.1250) No No T136T T136R No No No
Small GTPase (LmjF36.5880) No No F179F F179L No No No
L. major and L. infantum (Li) genes potentially involved in miltefosine (MF) resistance were sequenced. Heterozygous and homozygous mutations are indicated.
*- Stop codon. No – no mutation. ND – Not done.
doi:10.1371/journal.pntd.0001512.t002
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We sequenced two L. major MF-resistant mutants in order to
identify mutations putatively associated with MF resistance. Our
strategy was based on sequencing two independent resistant strains
and to assess the role in resistance of recurrent mutations.
Leishmania often amplifies regions of its genome in response to drug
selection [40,41], but this does not appear to be the case for the
MF resistant strains as determined by read depth sequence analysis
(Fig. S1A–C) and also further confirmed by comparative genomic
hybridization experiments (unpublished observations). The ab-
sence of amplicons in our MF-resistant L. major is consistent with
the previous characterization of MF resistant strains of L. donovani
[25]. However, the analysis revealed the presence of point
Figure 2. Mutations in the miltefosine transporter (MT) and pyridoxal kinase (PK) in the MF80.3 lineage. The top and bottom half circle
represents the MT and PK genes respectively. White represents wild-type sequences; semi-colored an heterozygous mutation and fully colored an
homozygous mutation. The type of mutation is also indicated.
doi:10.1371/journal.pntd.0001512.g002
Table 3. Mutations potentially involved in miltefosine resistance in the MF80.5 lineage.
Mutants/genes Miltefosine transporter (LmjF13.1530) Pyridoxal kinase (LmjF30.1250) a-adaptin like protein (LmjF07.0050)
MF5.5 No mutation G269D/G269G No mutation
MF10.5 No mutation G269D/G269G No mutation
MF20.5 G852D/G852G G269D/G269G No mutation
MF40.5 G852D/G852G G269D/G269G No mutation
MF60.5 G852D G269D/G269G No mutation
MF80.5 G852D G269D/G269G D762H
Heterozygous and homozygous mutations are indicated.
doi:10.1371/journal.pntd.0001512.t003
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mutants (Table 1). Three mutations were found in more than one
mutant: the miltefosine transporter MT LmjF13.1530, the
pyridoxal kinase PK LmjF30.1250, and the a-adaptin like protein
LmjF07.0050 (Table 2).
The MT protein is a P-type ATPase that mediates the inward
translocation of MF and glycerophospholipid analogues in
Leishmania [9,12]. The acquisition of inactivating mutations in
the MT gene was shown to be a major determinant of resistance to
MF in L. donovani and it appears that several distinct mutations in
MT can confer resistance in both promastigote and amastigotes
parasites [9,20]. The mutant Li MF200.5 with the MT gene
mutated, was indeed shown to be MF resistant using an
intramacrophagic essay (results not shown). Although several
distinct MT point mutations have also been identified in our panel
of L. major MF-resistant mutants (Table 2), they all differed from
those previously reported in L. donovani. These mutations were
located at conserved residues within the P-type ATPase protein
(Fig. S2). The number of mutated alleles in MT correlated with the
level of resistance to MF with the most resistant strains being
homozygous mutants. Mutations in MT only occur at later step of
drug selection (Fig. 2, Table 3).
Prior to MT mutations, the only other recurring mutation in
low-level resistant cells was the acquisition of the T216M or
G269D amino acid substitutions in the PK gene. Similarly as for
MT, the level of MF resistance correlated with the number of
mutated PK alleles in the MF 80.3 lineage (Fig. 2). As explained in
the result section, it is possible that mutations in MT happens in a
minority population of cells with heterozygous PK alleles and this
could explain how cells appear to be mostly homozygous for a
mutant allele in PK (15.3), and then becomes heterozygous (40.3)..
Pyridoxal-59-phosphate (PLP) is the active form of vitamin B6 and
is an essential cofactor of several enzymes, predominantly involved
in the transformation of amino acids [46,47]. Leishmania cannot
synthesize PLP de novo and rely on the scavenging of vitamin B6
precursors like pyridoxal, pyridoxine and pyridoxamine [48]. PK
was shown to catalyze the ATP-dependent phosphorylation of
these precursors and to play an essential role in the formation of
the biologically active PLP [46]. The role of PK in MF
susceptibility warrants further studies and may be due to the
many roles of PLP in cell physiology. Point mutations in PK are
found in the four L. major MF-resistant mutants (Table 2) and
transfection of a wild-type gene in MF15.3 restored susceptibility
(Fig. 5). Mutations in PK were not observed in MF resistant L.
infantum (Table 2), possibly suggesting additional species-specific
differences. For example, the expression of the MF translocation
machinery was found to vary between species and this altered their
MF susceptibilities [15]. Mutations in PK were in conserved
regions between Leishmania and other species but not in active sites
(Fig. S4), suggesting that the mutated PK possibly retains activity.
These mutations may modulate activities necessary to mitigate the
effect of MF. Reintroduction of wild-type alleles eliminates this
selective advantage. Our inability to generate a PK null mutant
may suggest that this gene is essential and cells lacking one allele
were shown to be more susceptible showing that PK is not likely to
be a target of MF and that other activities of PK or some
enzymatic reactions requiring PLP are essential to deal with MF
stresses. MF was shown to induce cellular events similar to those
resulting from alterations in the metabolism of PLP. Indeed, MF
Figure 3. Miltefosine susceptibilities of Leishmania major wild-
type and MF-resistant transfectants. The EC50 values were
determined by culturing promastigote parasites in the presence of
increasing concentrations of MF. The average of three independent
experiments is shown. LmjF WT (A), MF80.3 (B) and MF80.5 (C) parasites
were transfected with pSP72aHYGa (1); pSP72aHYGa-MT (2); pSP72a-
HYGa-MT* (G852D) (3); pSP72aHYGa-MT* (M547del) (4); pSP72aNEOa-
PK (5); and pSP72aHYGa-adaptin like protein (6). * p,0.01; ** p,0.001.
doi:10.1371/journal.pntd.0001512.g003
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and phosphatidylethanolamine (PE) in MF-sensitive but not MF-
resistant L. donovani parasites [19,49]. Interestingly, vitamin B6
deficiency in rat liver cells was shown to lead to a drastic reduction
in the methylation of PE to PC [50]. MF was also shown to induce
the accumulation of reactive oxygen species (ROS) in a dose-
dependent manner in Leishmania and this could be reverted by
reduced thiols [27]. The major reduced thiol in Leishmania is the
glutathione-spermidine conjugate trypanothione. The rate limiting
step of spermidine biosynthesis is catalyzed by the PLP-dependent
enzyme ornithine decarboxylase [51]. Moreover, vitamin B6 has
recently been associated with resistance to oxidative stresses and to
be itself an efficient scavenger of ROS [52]. Mutations in PK may
thus help in sustaining MF pressure by maintaining the PLP levels,
the homeostasis of phospholipids, or the redox state of the parasite.
Obviously, further experiments will be required to confirm these
hypotheses.
Other mutations were identified in the mutants MF80.3 and
MF80.5 but these were specific to a mutant with the exception of
the a-adaptin protein where mutations were also observed in two
L. infantum mutants (Table 2). However, these mutations occurred
only in the latest step of selection and transfection of the a-adaptin
gene did not change MF susceptibility (Fig. 3). While most of the
other mutated genes code for hypothetical proteins and are found
in single mutants they may be worth further investigating in
additional studies.
This study highlighted a number of concepts of general interest
in the genesis of drug resistance with also possible practical
implications. Resistance appears to be highly heterogeneous at the
level of the population with individual clones within the population
differing both in terms of genotype (Fig. 2) but also phenotype
(Fig. 4). This may be similar to the recent description of bacterial
charity where in a resistant bacterial population there are clones
with variable susceptibility, various clones helping others depend-
ing on the selective pressure [53]. This heterogeneity both in
genotype and phenotype in resistant populations may explain the
difficulties when studying field isolates. Analysis of drug resistance
in several clones may be more revealing than population analysis.
Indeed, the sequencing of the MF40.3 (or MF80.3) population
failed to highlight mutations in MT but the sequencing of several
clones showed mutations associated with resistance (Fig. 2). This
Figure 4. Miltefosine EC50 values of L. major parasites. Drug susceptibility of wild-type cells (white bars) and MF-resistant mutant population
(P) or clones (gray shaded bars) were measured. The clones were derived from MF5.3, MF10.3 and MF15.3 population and clone numbers are relate to
Fig. 2. The average of three independent measures is shown. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pntd.0001512.g004
Figure 5. Miltefosine susceptibilities of L. major parasites
transfected with the PK gene. The EC50 values were determined
by culturing promastigotes parasites in the presence of increasing
concentrations of MF. The average of three independent experiments is
shown. L. major MF15.3 transfected with the empty vector pSP72aNEOa
(1); pSP72aNEOa-PK (2); or pSP72aNEOa-PK* (T216M) (3). * p,0.05.
doi:10.1371/journal.pntd.0001512.g005
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www.plosntds.org 8 February 2012 | Volume 6 | Issue 2 | e1512Figure 6. Inactivation attempts of the L. major PK gene. (A) A schematic drawing of the PK locus with PstI sites. (B) Southern blot analysis of L.
major genomic DNA digested with PstI and hybridized with a 39 UTR probe of PK gene (a 600 bp fragment just upstream the stop codon of PK gene).
Lane 1, L. major wild-type; lane 2, L. major with one PK allele disrupted with the NEO marker; lane 3, L. major with two alleles disrupted (HYG and
NEO). Molecular weight is indicated on the right and the alleles are indicated on the left. (C) Miltefosine susceptibilities of Leishmania major wild-type
(1), SKO-PK (2) and SKO-PK complemented with a wild-type PK gene (3) parasites. The EC50 values were determined by culturing promastigotes
parasites in the presence of increasing concentrations of MF. The average of three independent experiments is shown. * p,0.01.
doi:10.1371/journal.pntd.0001512.g006
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mutations, with mutations during the selection of resistance in
PK arising always before mutations in MT and heterozygous
mutation being more frequent in the lower resistant cells and
homozygous mutations prevailing in more resistant isolates.
Whole genome sequencing is becoming a useful technique to
study resistance in bacteria [54–58] and presently applied to the
larger parasite genomes [59,60]. This study pinpointed known
and new resistance markers and also allowed the demonstration
of the polyclonal nature of a resistant population with individual
cells with varying susceptibility and genotypes. In further studies
we hope to study more deeply the clonal variety within a resistant
population and how these contribute to either resistance or
fitness, as recently highlighted for a population of resistant
bacteria [53].
Supporting Information
Figure S1 Copy number sequencing analysis for all
Leishmania chromosomes for L. major Friedlin wild-
type parasites (A) and the mutants MF80.3 (B) and
MF80.5 (C). The 36 chromosomes have been mapped as circles
representing the normalized read counts for each chromosome
(blue line). For the MF80.3 and MF80.5 mutants, the log2 ratios
of normalized read counts compared to the L. major Friedlin wild-
type reference are shown as black lines. Log2 ratios of at least 1
are shown in green and log2 ratios of at least 21a r es h o w ni n
red. Methods - Sequence reads were aligned with BWA (Burrow-
Wheeler Alignment) [36] and alignments were outputted in the
SAM (Sequence Alignment/Map) format [37]. Read alignment
positions were grouped in 4 kb windows [61] and the number of
reads in each window was normalized by multiplying it with the
ratio of the total number of reads for the L. major Friedlin wild-
type compared to the total number of reads obtained for the
corresponding resistant mutant. This allowed us to remove the
bias associated to the different number of reads per sequencing
run. For each sample, a ratio was computed for each window in
respect to the corresponding window in the reference sample (to
remove some biases such as GC bias). The logarithm in base 2
was then computed for each ratio to reduce the span of observed
values and to obtain a continuous spectrum [62]. Data was
plotted in a circular fashion using Circos, a versatile information-
aesthetic framework for data visualisation [63]. Log-2 ratios of at
least 1 are shown in green whereas of at least 21a r es h o w ni n
red.
(TIF)
Figure S2 Protein sequence alignment of L. major MT
(LmjF13.1530) with its respective orthologs of L.
infantum (LinJ13_V3.1590) and L. braziliensis (LbrM13_
V2.1380). Alignment was performed using the ClustalW
algorithm implemented in the Lasergene software (DNASTAR,
Inc.). Identical residues are shaded in black. The amino acids
mutated in the MT of L. major MF mutants are marked by the
lower arrowheads.
(TIF)
Figure S3 Protein sequence alignment of L. majora-
adaptin like protein (LmjF07.0050) with its respective
orthologs of L. infantum (LinJ07_V3.0060) and L.
braziliensis (LbrM7_V2.0050). Alignment was performed
using the ClustalW algorithm implemented in the Lasergene
software (DNASTAR, Inc.). Identical residues are shaded in black.
The amino acids mutated in the a-adaptin like protein of L. major
and L. infantum MF mutants are marked by the lower arrowheads.
(TIF)
Figure S4 Protein sequence alignment of L. major PK
(LmjF31.1250) with its respective orthologs of L.
infantum (LinJ13_V3.1590), L. braziliensis (LbrM13_
V2.1380), T. brucei (Tb06.5F5.240), E. coli (NP_416153)
and Homo sapiens (NP_003672). Alignment was performed
using the ClustalW algorithm implemented in the Lasergene
software (DNASTAR, Inc.). Identical residues are shaded in black.
The amino acids mutated in the PK of L. major MF mutants are
marked by the lower arrowheads.
(TIF)
Table S1 Primers used in this study for amplifying the
genes MT (LmjF13.1530), PK (LmjF30.1250) and the a-
adaptin like protein (LmjF07.0050) of L. major. Restriction
sites are underlined. Primers are also listed to sequence the genes
MT, the a-adaptin like protein and Ros3 (LmjF32.0510) of L. major
and to generate PK-KO constructs.
(DOC)
Table S2 Homozygous SNPs found after resequencing
the genome of L. major Friedlin. All the SNPs were identified
in L. major Friedlin wild-type and in the mutants MF80.3 and
MF80.5. The symbol * corresponds to a potential stop codon.
(DOC)
Table S3 Heterozygous allelic polymorphisms in L.
major Friedlin. All the same SNPs were identified in L. major
Friedlin wild-type and in the mutants MF80.3 and MF80.5.
(DOC)
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